

ZIKA CONGENITAL CASE INVESTIGATION FORM



NCIMS ID:	Date of notification:	Date of interview:
-----------	-----------------------	--------------------

DEMOGRAPHIC DETAILS

First Name:		Surname:		DOB:	
Address:		Suburb:		Postcode:	
Phone (home):		Phone (mobile):		Email:	
Indigenous status: <input type="checkbox"/> Aboriginal <input type="checkbox"/> Torres Strait Islander <input type="checkbox"/> Neither <input type="checkbox"/> Aboriginal & Torres Strait Islander <input type="checkbox"/> Unknown		Country of birth: <input type="checkbox"/> Australia <input type="checkbox"/> Other:		Language of Parent: <input type="checkbox"/> English <input type="checkbox"/> Other:	
Interpreter required for case interview: <input type="checkbox"/> Yes <input type="checkbox"/> No Job Number: _____					
MOTHER'S DETAILS:		First Name:		Surname:	
Is Mother a known Zika Case on NCIMS?		<input type="checkbox"/> Yes		<input type="checkbox"/> No	
- If Yes, NCIMS ID:		Classification:		<input type="checkbox"/> Confirmed <input type="checkbox"/> Probable <input type="checkbox"/> Suspected	

LABORATORY EVIDENCE *

1. Isolation of Zika virus by culture 'Zika virus culture'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Specimen type: <input type="checkbox"/> Serum Other: _____ Collection date: _____			
2. Detection of Zika virus by nucleic acid testing (PCR) 'Zika virus PCR'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Specimen type: <input type="checkbox"/> Serum Other: _____ Collection date: _____			
3. Detection of Zika antibody in serum ** 'Zika virus IgM/IgG antibody IA'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Sample 1: Collection date: _____ <input type="checkbox"/> IgM detected Titre: _____ <input type="checkbox"/> IgG detected Titre: _____	Sample 2: Collection date: _____ <input type="checkbox"/> IgM detected Titre: _____ <input type="checkbox"/> IgG detected. Titre: _____	Assessment: <input type="checkbox"/> No significant changes <input type="checkbox"/> IgG seroconversion <input type="checkbox"/> Significant rise in Ab <input type="checkbox"/> x4 or greater rise in IgG	
4. Detection of Zika IgM antibody in cerebrospinal fluid 'Zika virus IgM antibody IA'	<input type="checkbox"/> Yes <input type="checkbox"/> No	Results: <input type="checkbox"/> Zika IgM detected.	Other results: <input type="checkbox"/> Dengue IgM negative <input type="checkbox"/> MVE IgM negative <input type="checkbox"/> West Nile / Kunjin virus IgM negative <input type="checkbox"/> Japanese encephalitis (JE) virus IgM negative		
5. Specimen(s) sent to arbovirus reference lab (ICPMR or QHFSS) for parallel testing or confirmation? <input type="checkbox"/> Yes <input type="checkbox"/> No Date sent: _____					

Note: * Confirmation of the result by an arbovirus reference laboratory is recommended
 ** If ZIKV-specific IgG was initially negative and subsequent testing greater than 4 weeks after exposure fails to demonstrate seroconversion the case should be excluded. Refer to the Confirmed or Probable case definitions (see page 2).

CLINICAL EVIDENCE

6. Were there clinical signs?	<input type="checkbox"/> Yes <input type="checkbox"/> No				
Microcephaly	<input type="checkbox"/> Yes <input type="checkbox"/> No	If Yes, diagnosed pre-natally by ultrasound?	<input type="checkbox"/> Yes <input type="checkbox"/> No	Diagnosed at birth?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Other neurological abnormality	<input type="checkbox"/> Yes <input type="checkbox"/> No	Details: _____			
Other abnormality	<input type="checkbox"/> Yes <input type="checkbox"/> No	Details: _____			

PREGNANCY / INFANT BIRTH DETAILS

7. Is the case in a fetus or an infant?		<input type="checkbox"/> Fetus <input type="checkbox"/> Infant	
If fetal case:	Gestational age: _____	weeks	
	Expected delivery date: _____		
If infant case:	Delivery date: _____		
	Gestational age of baby at delivery: _____	weeks	

ZIKA CONGENITAL CASE INVESTIGATION FORM



EVENT OUTCOME

8. Was the baby hospitalised?	<input type="checkbox"/> Yes <input type="checkbox"/> No	Details: _____ _____
9. Outcome:	<input type="checkbox"/> Alive <input type="checkbox"/> Dead <input type="checkbox"/> Unknown	Date of death: _____ (if applicable)
10. Place of disease acquisition (for the Mother)	<input type="checkbox"/> Outside of Australia <input type="checkbox"/> In Australia, outside of NSW* <input type="checkbox"/> In NSW* <input type="checkbox"/> Unknown	
11. Country of disease acquisition (for the Mother)	_____ (Regions can also be selected, e.g. South-East Asia)	

* Note: If a case is believed to have been acquired in NSW or elsewhere in Australia, contact CD OnCall immediately.

CASE MANAGEMENT

13. Has the case been referred for specialist Paediatric assessment and management? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
If Yes, Paediatrician details (Name, Address, Phone): _____
If No or unknown, action taken: _____

BACKGROUND INFORMATION ON CONGENITAL ZIKA

- There is strong scientific consensus that pregnant women who become infected with ZIKV can transmit the infection to their unborn babies, with potentially serious consequences.
- Reports from many countries where ZIKV outbreaks have occurred indicate an association between maternal infection and risk of severe congenital abnormalities, including microcephaly.
- While the risk appears greatest with infection in the first trimester, the risk of congenital abnormalities and complications appears to relate to all trimesters of pregnancy.
- Maternal ZIKV infection is not believed to pose a risk of birth defects for future pregnancies.

ZIKA CONGENITAL CASE DEFINITIONS *

A CONFIRMED Congenital Zika case requires: <ul style="list-style-type: none"> • Laboratory definitive evidence only. (cases are further classified as Fetal or Infant) 	A PROBABLE Congenital Zika case requires: <ul style="list-style-type: none"> • Clinical evidence AND epidemiological evidence. (cases are further classified as Fetal or Infant)
Laboratory definitive evidence Fetal case (at 20 weeks gestation or more): <ul style="list-style-type: none"> • Isolation or detection of ZIKV from appropriate clinical samples (i.e. fetal blood, amniotic fluid, chorionic villus sample or post-mortem cerebrospinal fluid or tissue) by viral culture or nucleic acid testing. Infant (within 28 days following birth): <ul style="list-style-type: none"> • Isolation or detection of ZIKV from appropriate clinical samples by viral culture or nucleic acid testing, with no history of travel since birth to, or residence in, a ZIKV receptive country or area in Australia 	Clinical evidence <ul style="list-style-type: none"> • Microcephaly or other CNS abnormalities in the infant or fetus (in the absence of any other known cause). Epidemiological evidence <ul style="list-style-type: none"> • Confirmed or probable ZIKV infection in the mother during pregnancy.*

Note: * See the Zika control guidelines for other Zika case definitions.

ADDITIONAL NOTES:
